What You Don’t Know About AMP Can Hurt You – Part 3 Can You Defend Your AMP?
As part of a three-part series on the Average Manufacturer Price (AMP), this month’s article explores the continuing and evolving scrutiny on AMP by the OIG, and the focus on a manufacturer’s accurate methodologies and reasonable assumptions related to the calculation of AMP.
In the previous two articles, we looked at the origins of AMP in the Medicaid Drug Rebate Program, and its evolution over the last 25 plus years through regulatory changes, injunctions, and legislation. This month we ask what should be a relatively simple question, why the continued scrutiny by the government on AMP?
Related Posts
Read Full Article in the October 2016 Issue of Life Science Compliance Update